Nepetoidin B ( **1** ) was initially isolated from *Plectranthus caninus* in 1975 as the ( *Z* , *E* )- **1** isomer (Figure [1](#FI000-1){ref-type="fig"} ). [@JR000-1] Since then, ( *Z* , *E* ) *-* **1** and its corresponding stereoisomer, ( *E* , *E* )- **1** , have been isolated from a variety of plant species using solvent extraction and chromatographic purification. [@JR000-2] . The amounts of ( *Z* , *E* )- **1** and ( *E* , *E* )- **1** vary from 9:1 to 1:1 in different plants, [@JR000-1] [@JR000-10] where the stereochemistry of the two isomers has historically been elucidated based on the analyses of *J* -coupling constants from NMR spectroscopic data. [@JR000-1] [@JR000-2] [@JR000-3] [@JR000-4] [@JR000-5] [@JR000-6] [@JR000-7] [@JR000-8] [@JR000-9] [@JR000-12] [@JR000-15] [@JR000-16] [@JR000-17] [@JR000-18] [@BR000-19] [@OR000-20]

Nepetoidin's level in plants is rather low; in a recent isolation from 100 kg of *Salvia miltiorrhiza* Bunge (Danshen), extraction and purification yielded just 37 mg. [@JR000-27] Based on the genes, enzymes, and metabolites that have been associated with nepetoidin B, several mechanisms have been proposed for its biosynthesis: (1) condensation of the enol form of dopaldehyde with caffeic acid; [@JR000-1] [@JR000-5] [@JR000-15] [@BR000-19] (2) oxidative decarboxylation of rosmarinic acid, from which stereo­specific loss of the pro- *R* or pro- *S* methylene proton during this process would result in the formation of ( *Z* , *E* )- **1** or ( *E* , *E* )- **1** ; [@JR000-21] [@JR000-25] and (3) decarboxylation of *p* -hydroxyphenyl­pyruvic acid and subsequent esterification with the enol form of 3,4-dihydroxyphenylacetaldehyde. [@JR000-25]

Several studies have demonstrated potential biological applications for **1** : it has shown antibacterial, antifungal, and free-radical scavenging properties, and it could be used as a chemotaxonomic marker. [@JR000-8] [@JR000-9] [@JR000-10] [@JR000-12] [@JR000-15] [@JR000-30] [@JR000-31] Furthermore, **1** is an inhibitor of xanthine oxidase and thus could help to regulate hyperuricemia in human gout, [@JR000-12] as well as inhibit the production of nitric oxide, which is stimulated by bacterial lipopolysaccharide. [@JR000-27] Surprisingly, in spite of its medicinal characteristics, there has been no reported synthesis of **1** to date. The commercial price of nepetoidin B varies from about \$150/mg to about \$5,000/g, a price prohibitive to its use in research studies. In continuation of our work on the production of bioproducts from biomass, especially with regard to nepetoidin B and its potential incorporation into lignin in plant cell walls, we sought to design a synthetic route for its production. [@JR000-32]

![The two naturally occurring isomers of nepetoidin B, ( *Z* , *E* )- **1** and ( *E* , *E* )- **1** , isolated from plants](i_b0110_f1_10-1055_s-0036-1591556){#FI000-1}

Herein, we report the first synthesis of nepetoidin B. Our synthetic route (Scheme [1](#CS000-1){ref-type="chem"} ) began with Baeyer--Villiger oxidation of commercially available 1,5-bis(3,4-dimethoxyphenyl)-1,4-pentadien-3-one ( **2** ) with oxone, based on a reported procedure for the transformation of α,β-unsaturated ketones into their corresponding vinyl acetates. [@JR000-33] We optimized the reaction conditions for the stereospecific transformation of only one of the two symmetrical α,β-unsaturated ketones into its corresponding vinyl acetate; our final conditions afforded tetramethylated nepetoidin B \[( *E* , *E* )- **3** isomer\] in an isolated yield of 40% from **2** , with the starting material being recovered in an isolated yield of 37% (i.e., the overall conversion of starting material to product was about 63%). It is interesting to note that we did not observe iso­merization of ( *E* , *E* )- **3** to ( *Z* , *E* )- **3** during the Baeyer--Villiger oxidation of **2** . After optimizing the demethylation of **3** ­using boron tribromide, we obtained **1** in an isolated yield of 43%, thus completing our two-step synthesis of nepetoidin B in an overall yield of 17% (33% when the recovery of starting compound **2** is taken into account).

###### 

**Scheme 1** Synthesis of nepetoidin B
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Synthetic nepetoidin B was obtained as a mixture of the two isomers in a ratio of 94:6 ( *E* , *E* )- **1** /(Z, *E* )- **1** (as estimated by ^1^ H NMR analysis; Figures S1 and S2 in the Supporting ­Information). Considering that the ( *E* , *E* )- **1** isomer was the predominant product in our synthesis, it appears to be the thermodynamically favored isomer. The mixture of the isomers of nepetoidin B \[( *E* , *E* )- **1** 94% and ( *Z* , *E* )- **1** 6%\] was separated by HPLC. [@OR000-34]

In conclusion, we have described the first synthesis of nepetoidin B. Currently, commercial sources charge about \$5,000/g for the product, and so we expect that this convenient synthesis could allow for nepetoidin B to be manufactured at a significantly reduced cost of about \$500/g. Its ­potential value as a medicinal compound would seem to make this a worthwhile venture.
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